Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Feb 12, 2015 2:24pm
165 Views
Post# 23423179

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:News Release Issued: Feb 10, 2015 (12:00pm MST)

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:News Release Issued: Feb 10, 2015 (12:00pm MST)fouremm, thank you as always for your excellent post(s) which are always objective, insightful and provide and/or remind us of previously published very relevant information.

I find everything you've said in this post highly relevant and encouraging. Of particular note is your last line in the first paragraph

"The post hoc analysis of SUSTAIN revealed the first set of great MACE results and this was the reason that MACE was a pre-specified secondary endpoint in ASSURE."

I did not know that MACE it was pre-selected! (as opposed to just part of the post hoc analysis.

AND NOW FOR SOMETHING COMPLETELY DIFFERENT (as Monty Python fans would say)
Now, on a different and somewhat non-objective bit of foolery I was thinking about the share price and share structure. As I see it RVX has 80 million share issued and from my trading account it seems like there are 66 million being traded on the TSX. I don't know if the 14 million are being held in reserve for issue to raise funds in the future if the share prive goes up. So let us assume that in order to get control of RVX a buyer would need say 51% ownership of 80 million shares which would be 40.8 million shares. From what I recall Eastern/KD owns 20% or 16 million shares. NGN owns 8 million or 10%. I don't know what Don, management and other insiders own but that information was available in the spinco documents. I don't have the time to look that up right now. Now let's say someone started buying RVX shares in small batches through 5 or 6 or more different brokerages and ended up paying, say $2/per share by the completion of accumulating 51%. So they would end up taking control for $81,600,000 or less. It seems to me to be a very small amount of money for someone willing to bet on the risk at a phase III trial given the potential returns generated by rvx-208 over a 20 year (or whatever) patent protected period.

Of course Don would need to mount a defense and Eastern and NGN would not sit idly by twiddling their thumbs. I've been shot down in flames, and rightly so, buy other posters when I floated this idea a year ago but if it sparks any thoughts let them fly.

Anyway, back to the main point. fouremm, and other posters it seems that we are at a stage where there has been so much important, objective information published by posters from both the scientific side as well as other perspectives that we are at a stage of needing a summary of key findings. The science side, as illustrated by fouremms post today is particularly important because question coming up currently have been addressed previously. RVX won't do it because communications is not important to them. It would be nice to have a bullet point summary of key scientific findings ( + and -) of the last 2 years. I don't have the skills to do it but perhaps there is a way.

Apologies for my "take over" foolery.
Cheers
Toinv    :)

Bullboard Posts